

Novel Hybrid Series of Compound Derived from 2-Aminotetralin and Piperazine Based Derivatives: Characterization for D1, D2, D3, D4 and other Serotonin Receptor Subtypes Binding

Published date: May 6, 2010

Technology description

A series of compounds derived from 2-aminotetralin and piperazine fragments have been synthesized, which exhibit high CNS activity in vivo and in vitro. Some of the selected lead compounds have exhibited potent in vivo activity in a Parkinson's disease animal model with long extended duration of action. In particular, these compounds show high D3 receptor affinity and/or high D3/D2 selectivity. In addition to the potential therapeutic treatment of Parkinson's disease and depression, these novel compounds have possible application in the treatment of a number of other neurological disorders such as cocaine addiction, restless leg syndrome or as an atypical antipsychotic agent.

Application area

- Atypical Antipsychotics
- Medication for Neurodegenerative Diseases
- Anti-depressants
- Treatment of Addiction

Institution

[Wayne State University](#)

Inventors

[Aloke Dutta](#)

Professor

Pharmaceutical Sciences

[Xiang-Shu Fei](#)

Post Doctoral Associate

联系我们



叶先生

电话 : 021-65679356

手机 : 13414935137

邮箱 : yeyingsheng@zf-ym.com